35 completed, 9 terminated, 4 unknown, 2 withdrawn. 34 Phase 2, 12 Phase 1, 5 Phase 3, 3 Not applicable.
Follow Adenocarcinoma of the Gastroesophageal Junction: new trials by email Literature Review of Adenocarcinoma of the Gastroesophageal Junction trials Research Report on Adenocarcinoma of the Gastroesophageal Junction
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Induction FLOT With CROSS CRT for Esophageal Cancer Sequential FLOT followed by chemoradiation - Adenocarcinoma Esophagus, Adenocarcinoma of the Gastroesophageal Junction | Phase 2 | Active not recruiting | University of Colorado, Denver | 40 | 2020-04-08 | 2026-01-09 |
| Regorafenib Combined With Irinotecan as Second-line in Patients With Metastatic Gastro-oesophageal Adenocarcinomas Regorafenib and Irinotecan, Irinotecan - Adenocarcinoma of the Stomach, Adenocarcinoma of the Gastroesophageal Junction | Phase 1 / Phase 2 | Terminated | UNICANCER | 89 | 2019-02-07 | 2023-10-16 |
| Study of Guanábana Leaves for The Treatment of Patients With Gastric, Gastroesophageal Junction, Pancreatic and Colorectal Adenocarcinomas; Hepatocellular Carcinoma, and Low Grade Lymphomas Tea Made of Graviola Leaves - Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction | Not applicable | Unknown | Auxilio Mutuo Cancer Center | 54 | 2018-11-07 | 2021-02-26 |
| Perioperative Chemo and Pembrolizumab in Gastric Cancer Pembrolizumab, Standard of care chemotherapy regimen - Gastric Cancer, Adenocarcinoma of the Gastroesophageal Junction | Phase 2 | Completed | Gulam Manji | 49 | 2017-11-25 | 2024-02-15 |
| Assessment of Metabolic & Path Response w/ RCT & ImT Before Surgery in Locally Advanced Esoph and Gastro-esoph Jction CA Monalizumab, Oxaliplatin, 5-Fluorouracil - Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction | Phase 1 / Phase 2 | Withdrawn | Jules Bordet Institute | 2017-07-20 | 2017-12-19 | |
| Resilience and Exercise in Advanced Cancer Treatment Band Together, Exercise Education - Pancreatic Adenocarcinoma, Gastric Adenocarcinoma | Not applicable | Completed | Milton S. Hershey Medical Center | 14 | 2015-12-01 | 2018-02-28 |
| FDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced Stomach or Gastroesophageal Junction Cancer FDG-PET, surgery, 5-FU - Adenocarcinoma of the Gastroesophageal Junction, Gastric Adenocarcinoma | Phase 2 | Terminated | Alliance for Clinical Trials in Oncology | 5 | 2015-11-12 | 2025-01-20 |
| A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer Ramucirumab, Pembrolizumab - Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction | Phase 1 | Completed | Eli Lilly and Company | 175 | 2015-07-29 | 2024-07-31 |
| C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer c-Met inhibitor AMG 337, placebo, oxaliplatin - Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction | Phase 1 / Phase 2 | Withdrawn | Eastern Cooperative Oncology Group | 2015-03-06 | 2023-05-25 | |
| 64Cu DOTA-Trastuzumab PET/CT in Studying Patients With Gastric Cancer copper Cu 64-DOTA-trastuzumab, positron emission tomography, laboratory biomarker analysis - Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach | Not applicable | Completed | City of Hope Medical Center | 8 | 2014-11-19 | 2025-02-28 |
| Regorafenib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction Who Have Completed Chemoradiation Therapy and Surgery Placebo, Regorafenib - Adenocarcinoma of the Gastroesophageal Junction, Stage IIB Esophageal Adenocarcinoma | Phase 2 | Terminated | Academic and Community Cancer Research United | 3 | 2014-09-01 | 2018-10-17 |
| A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab DKN-01 150 mg, Paclitaxel, Pembrolizumab - Esophageal Neoplasms, Adenocarcinoma of the Gastroesophageal Junction | Phase 1 | Completed | Leap Therapeutics, Inc. | 151 | 2014-05-05 | 2025-08-03 |
| FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma oxaliplatin, leucovorin calcium, fluorouracil - Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction | Phase 2 | Unknown | Case Comprehensive Cancer Center | 63 | 2014-02-10 | 2024-01-08 |
| Second-line Treatment With Icotinib in Esophageal Carcinoma Patients With EGFR Overexpression (IHC 3+) or Positive FISH Icotinib - Adenocarcinoma of the Gastroesophageal Junction, Esophageal Carcinoma | Phase 2 | Completed | Betta Pharmaceuticals Co., Ltd. | 54 | 2013-05-01 | 2019-07-05 |
| Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery cyclodextrin-based polymer-camptothecin CRLX101, Laboratory biomarker analysis, Pharmacological studies - Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction | Phase 2 | Completed | City of Hope Medical Center | 10 | 2012-11-01 | 2018-02-01 |
| Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery Akt inhibitor MK2206, trastuzumab, lapatinib ditosylate - Adenocarcinoma of the Gastroesophageal Junction, HER2-positive Breast Cancer | Phase 1 | Terminated | National Cancer Institute (NCI) | 60 | 2012-09-01 | 2013-09-30 |
| S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer FOLFOX regimen, docetaxel, fluorouracil - Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer | Phase 2 | Completed | SWOG Cancer Research Network | 213 | 2012-02-01 | 2019-11-07 |
| Everolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal Cancer fluorouracil, leucovorin calcium, oxaliplatin - Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction | Phase 1 / Phase 2 | Completed | City of Hope Medical Center | 6 | 2012-02-01 | 2017-05-31 |
| Efficacy and Safety Study of the Combined Modality Therapy in Adenocarcinoma of the Esophago-gastric Junction preoperative chemo- and chemoradiotherapy, Surgical resection - Adenocarcinoma of the Gastroesophageal Junction | Phase 2 / Phase 3 | Unknown | Medical University of Lublin | 100 | 2012-01-01 | 2013-02-05 |
| Explorative Phase II Study of Perioperative Treatment in Patients With Adenocarcinoma of the Gastroesophageal Junction or Stomach 5-FU, leucovorin, docetaxel, oxaliplatin (FLOT), trastuzumab, Post-operative treatment trastuzumab mono therapy - Adenocarcinoma of the Gastroesophageal Junction, Adenocarcinoma of the Stomach | Phase 2 | Completed | AIO-Studien-gGmbH | 53 | 2011-12-01 | 2017-06-19 |
Showing 20 of 52. Sign in to see all of them.
Stomach Neoplasms (30) · Esophageal Neoplasms (28) · Adenocarcinoma Of Esophagus (24) · Esophageal Squamous Cell Carcinoma (10) · Adenocarcinoma (4) · Endometrial Neoplasms (4) · Ovarian Neoplasms (4) · Fallopian Tube Neoplasms (3) · Sarcoma (3) · Uterine Cervical Neoplasms (3) · Vaginal Neoplasms (3) · Vulvar Neoplasms (3) · Carcinoma, Squamous Cell (2) · Biliary Tract Neoplasms (1) · Breast Neoplasms (1)
Neoplasms (47) · Digestive System Diseases (44) · Digestive System Neoplasms (44) · Neoplasms by Site (44) · Gastrointestinal Diseases (42) · Gastrointestinal Neoplasms (41) · Esophageal Diseases (30) · Head and Neck Neoplasms (30) · Stomach Diseases (30) · Neoplasms by Histologic Type (21) · Carcinoma (19) · Neoplasms, Glandular and Epithelial (19) · Neoplasms, Squamous Cell (12) · Carcinoma, Squamous Cell (10) · Female Urogenital Diseases (5)
Fluorouracil (19) · Oxaliplatin (16) · Docetaxel (11) · Leucovorin (11) · Cisplatin (8) · Irinotecan (8) · Radiotherapy (7) · Capecitabine (5) · Paclitaxel (5) · Radiation (4) · Carboplatin (3) · Lapatinib (3) · Neoadjuvant Therapy (3) · Surgical Procedures, Operative (3) · pembrolizumab (3)
National Cancer Institute (NCI) (11) · Alliance for Clinical Trials in Oncology (5) · Case Comprehensive Cancer Center (3) · City of Hope Medical Center (3) · Royal Marsden NHS Foundation Trust (3) · Fox Chase Cancer Center (2) · Leap Therapeutics, Inc. (2) · AIO-Studien-gGmbH (1) · Academic and Community Cancer Research United (1) · Auxilio Mutuo Cancer Center (1) · Betta Pharmaceuticals Co., Ltd. (1) · Cambridge University Hospitals NHS Foundation Trust (1) · Cancer Research UK (1) · Eastern Cooperative Oncology Group (1) · Eli Lilly and Company (1)
United States (36) · United Kingdom (7) · France (4) · Germany (4) · Belgium (2) · Canada (2) · Austria (1) · China (1) · Hungary (1) · Italy (1) · Japan (1) · Poland (1) · Portugal (1) · Puerto Rico (1) · Spain (1)
Clare Shaw, Phd (3) · Yelena Janjigian (2) · A. Craig Lockhart, MD (1) · Afshin Dowlati, MD (1) · Agnieszka Fronczek, MD (1) · Allyson Ocean (1) · Amanda B Cooper, MD (1) · Amelie Deleporte, Physician (1) · Aminah Jatoi, MD (1) · Andreas Kaubisch (1) · Anna Brzozowska, MD, PhD (1) · Arnaud Roth (1) · Arthur Blackstock (1)
PMID 19738454, PMID 20458043, PMID 23553066, PMID 24526575, PMID 24562448, PMID 24728035, PMID 24982463, PMID 25827820, PMID 26980473, PMID 28078107, PMID 29635438, PMID 29853658, PMID 31301962, PMID 32111181, PMID 33055589, PMID 33068794, PMID 33934058, PMID 34019698, PMID 34077237, PMID 37046849, PMID 37856106
2009 (2), N01CM00038 (2), N01CM62204 (2), U10CA032102 (2), U10CA180821 (2), 2015 (1), 2016 (1), 2018 (1), N01CM00070 (1), N01CM00071 (1), N01CM17105 (1), N01CM62203 (1), N01CM62206 (1), P30CA006927 (1), P30CA008748 (1)